Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in vivo

29 Sept 2022

Abstract excerpt

"Pan-coronavirus" antivirals targeting conserved viral components can be designed. Here, we show that the rationally engineered H84T-banana lectin (H84T-BanLec), which specifically recognizes high mannose found on viral proteins but seldom on healthy human cells, potently inhibits Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to Phagocytosis and Immune Regulation
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36195094
DOI: 10.1016/j.xcrm.2022.100774

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in vivoPMID 36195094Read ↗

A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in vivoSemantic proximity Read ↗

Exploring lectin–glycan interactions to combat COVID-19: Lessons acquired from other enveloped virusesSemantic proximity Read ↗

Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2Semantic proximity Read ↗

A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including OmicronSemantic proximity Read ↗

Recognition and blocking of SARS-CoV-2 variants by Mannose-Binding LectinSemantic proximity Read ↗

Lentil lectin derived from Lens culinaris exhibit broad antiviral activities against SARS-CoV-2 variantsSemantic proximity Read ↗

Rational Development of Hypervalent Glycan Shield‐Binding Nanoparticles with Broad‐Spectrum Inhibition against Fatal Viruses Including SARS‐CoV‐2 VariantsSemantic proximity Read ↗

Targeting spike glycans to inhibit SARS-CoV2 viral entrySemantic proximity Read ↗

Targeting conserved N-glycosylation blocks SARS-CoV-2 variant infection in vitroSemantic proximity Read ↗

A genetically engineered therapeutic lectin inhibits human influenza A virus infection and sustains robust virus-specific CD8 T cell expansionSemantic proximity Read ↗

Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition moleculesSemantic proximity Read ↗

The Effect of Select SARS-CoV-2 N-Linked Glycan and Variant of Concern Spike Protein Mutations on C-Type Lectin-Receptor-Mediated Infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.